Is Opus Genetics, Inc. (IRD) overvalued? · rev $11.0M
Opus Genetics, Inc. (IRD) is a biotechnology company listed on US.
This page asks whether Opus Genetics, Inc. (IRD) looks expensive on cached numbers — not a short thesis.
Latest reported IRD revenue for 2024-12-31 was $11.0M. Net income was -$57.5M. Revenue was down 42.3% from 2023-12-31 to 2024-12-31. IRD currently screens at market cap $35.7M.
IRD currently screens at market cap $35.7M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next IRD 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the IRD stock page for the full model, not this heading.
Not investment advice.